Decorated nanoparticles prevent anaphylaxis without causing side effects in mouse study

Northwestern University researchers have developed the first selective therapy to prevent allergic reactions, which can range in severity from itchy hives and watery eyes to trouble breathing, and even death. To develop the new therapy, researchers decorated nanoparticles with antibodies capable of shutting down specific immune cells responsible for allergic responses. The nanoparticle also carries an allergen that corresponds to the patient's specific allergy. If a person is allergic to peanuts, for example, then the nanoparticle carries a peanut protein.